Homepage>Company>Media>Pharma News>2018>Phase II data support potential for Roche’s novel anti-VEGF/anti-angiopoietin-2 bispecific antibody, RG7716, for people with diabetic macular edema
Phase II data support potential for Roche’s novel anti-VEGF/anti-angiopoietin-2 bispecific antibody, RG7716, for people with diabetic macular edema